Last Price$61.4(0.0%)
Market Cap$7,773.1M
33.1%
Industry median - (169.7%)
5Y Historical average - 64.4%
24.5%
Industry median - (172.9%)
5Y Historical average - 57.0%
108.8%
Industry median - (41.2%)
5Y Historical average - 129.2%
22.3%
Industry median - (39.5%)
5Y Historical average - 20.9%
HALO Capital Allocation Rating
HALO Capital Allocation rating
7.0
HALO Capital Allocation rating performance
HALO Capital Allocation metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with HALO Capital Allocation
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Capital Allocation score | ROIC | ROIC - WACC | CROIC | ROE | ROCE | Shares count growth | Shareholder yield |
$7,773.1M | 7.0 | 33.1% | 24.5% | 35.4% | 108.8% | 22.3% | (1.7%) | 3.2% | |
$124.8B | 4.8 | (15.0%) | (22.6%) | (11.5%) | (3.3%) | (5.5%) | 0.1% | 1.3% | |
$77.0B | 6.0 | 25.7% | 18.1% | 25.3% | 13.7% | 10.3% | 1.4% | 4.1% | |
$34.4B | 4.2 | (41.3%) | N/A | (24.0%) | (4.8%) | (8.5%) | 2.2% | 0.0% | |
$30.7B | 3.9 | (7.2%) | (14.8%) | (4.0%) | (559.4%) | (2.6%) | 2.4% | 0.0% | |
$24.0B | 4.7 | (37.8%) | (45.6%) | (6.7%) | (3.5%) | (6.5%) | 0.8% | 0.0% | |
$14.5B | 5.5 | 14.5% | 9.6% | 37.0% | 12.9% | 6.4% | (2.8%) | 3.6% | |
$13.8B | 7.3 | 65.4% | 57.7% | 68.4% | 19.1% | 16.0% | (5.1%) | 7.3% | |
$13.4B | 6.2 | 11.0% | 3.5% | 15.1% | 7.7% | 5.5% | 1.0% | 0.5% | |
$13.3B | 4.5 | (3,335.4%) | (3,343.2%) | (2,216.2%) | (53.5%) | (51.1%) | 3.6% | 0.0% | |
$1,846.9M | 4.3 | (43.2%) | (47.6%) | (43.3%) | (25.3%) | (27.4%) | 1.2% | 0.0% |
FAQ
What is the Halozyme Therapeutics, Inc. (HALO) ROIC (Return on Invested Capital)?
The Halozyme Therapeutics, Inc. (HALO) ROIC is 33.1%, compared to the industry median of ((169.7%)) and the 5-year historical average of 64.4%.
What is the Halozyme Therapeutics, Inc. (HALO) ROIC minus WACC (Weighted Average Cost of Capital)?
The Halozyme Therapeutics, Inc. (HALO) ROIC minus WACC is 24.5%, compared to the industry median of ((172.9%)) and the 5-year historical average of 57.0%.
What is the Halozyme Therapeutics, Inc. (HALO) ROE (Return on Equity)?
The Halozyme Therapeutics, Inc. (HALO) ROE is 108.8%, compared to the industry median of ((41.2%)) and the 5-year historical average of 129.2%.
What is the Halozyme Therapeutics, Inc. (HALO) ROCE (Return on Capital Employed)?
The Halozyme Therapeutics, Inc. (HALO) ROCE is 22.3%, compared to the industry median of ((39.5%)) and the 5-year historical average of 20.9%.